These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 31011167)

  • 1. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies.
    Smith MA; Choudhary GS; Pellagatti A; Choi K; Bolanos LC; Bhagat TD; Gordon-Mitchell S; Von Ahrens D; Pradhan K; Steeples V; Kim S; Steidl U; Walter M; Fraser IDC; Kulkarni A; Salomonis N; Komurov K; Boultwood J; Verma A; Starczynowski DT
    Nat Cell Biol; 2019 May; 21(5):640-650. PubMed ID: 31011167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations.
    Choudhary GS; Pellagatti A; Agianian B; Smith MA; Bhagat TD; Gordon-Mitchell S; Sahu S; Pandey S; Shah N; Aluri S; Aggarwal R; Aminov S; Schwartz L; Steeples V; Booher RN; Ramachandra M; Samson M; Carbajal M; Pradhan K; Bowman TV; Pillai MM; Will B; Wickrema A; Shastri A; Bradley RK; Martell RE; Steidl UG; Gavathiotis E; Boultwood J; Starczynowski DT; Verma A
    Elife; 2022 Aug; 11():. PubMed ID: 36040792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. U2AF1 mutation promotes tumorigenicity through facilitating autophagy flux mediated by FOXO3a activation in myelodysplastic syndromes.
    Zhu Y; Song D; Guo J; Jin J; Tao Y; Zhang Z; Xu F; He Q; Li X; Chang C; Wu L
    Cell Death Dis; 2021 Jun; 12(7):655. PubMed ID: 34183647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Splicing factor mutations in the myelodysplastic syndromes: Role of key aberrantly spliced genes in disease pathophysiology and treatment.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2023 Jan; 87():100920. PubMed ID: 36216757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML.
    Bennett J; Ishikawa C; Agarwal P; Yeung J; Sampson A; Uible E; Vick E; Bolanos LC; Hueneman K; Wunderlich M; Kolt A; Choi K; Volk A; Greis KD; Rosenbaum J; Hoyt SB; Thomas CJ; Starczynowski DT
    Blood; 2023 Sep; 142(11):989-1007. PubMed ID: 37172199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperactivation of NF-κB signaling in splicing factor mutant myelodysplastic syndromes and therapeutic approaches.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2024 Oct; ():101055. PubMed ID: 39406588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome.
    Shirai CL; White BS; Tripathi M; Tapia R; Ley JN; Ndonwi M; Kim S; Shao J; Carver A; Saez B; Fulton RS; Fronick C; O'Laughlin M; Lagisetti C; Webb TR; Graubert TA; Walter MJ
    Nat Commun; 2017 Jan; 8():14060. PubMed ID: 28067246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of U2AF1 mutant in patients with de novo myelodysplastic syndromes: a meta-analysis.
    Wang H; Zhang N; Wu X; Zheng X; Ling Y; Gong Y
    Ann Hematol; 2019 Dec; 98(12):2629-2639. PubMed ID: 31754743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor suppressor microRNAs are downregulated in myelodysplastic syndrome with spliceosome mutations.
    Aslan D; Garde C; Nygaard MK; Helbo AS; Dimopoulos K; Hansen JW; Severinsen MT; Treppendahl MB; Sjø LD; Grønbæk K; Kristensen LS
    Oncotarget; 2016 Mar; 7(9):9951-63. PubMed ID: 26848861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.
    Pellagatti A; Armstrong RN; Steeples V; Sharma E; Repapi E; Singh S; Sanchi A; Radujkovic A; Horn P; Dolatshad H; Roy S; Broxholme J; Lockstone H; Taylor S; Giagounidis A; Vyas P; Schuh A; Hamblin A; Papaemmanuil E; Killick S; Malcovati L; Hennrich ML; Gavin AC; Ho AD; Luft T; Hellström-Lindberg E; Cazzola M; Smith CWJ; Smith S; Boultwood J
    Blood; 2018 Sep; 132(12):1225-1240. PubMed ID: 29930011
    [No Abstract]   [Full Text] [Related]  

  • 11. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
    Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
    BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant U2AF1-induced alternative splicing of H2afy (macroH2A1) regulates B-lymphopoiesis in mice.
    Kim SP; Srivatsan SN; Chavez M; Shirai CL; White BS; Ahmed T; Alberti MO; Shao J; Nunley R; White LS; Bednarski J; Pehrson JR; Walter MJ
    Cell Rep; 2021 Aug; 36(9):109626. PubMed ID: 34469727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant U2AF1-Induced Mis-Splicing of mRNA Translation Genes Confers Resistance to Chemotherapy in Acute Myeloid Leukemia.
    Jin P; Wang X; Jin Q; Zhang Y; Shen J; Jiang G; Zhu H; Zhao M; Wang D; Li Z; Zhou Y; Li W; Zhang W; Liu Y; Wang S; Jin W; Cao Y; Sheng G; Dong F; Wu S; Li X; Jin Z; He M; Liu X; Chen L; Zhang Y; Wang K; Li J
    Cancer Res; 2024 May; 84(10):1583-1596. PubMed ID: 38417135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
    Qian J; Yao DM; Lin J; Qian W; Wang CZ; Chai HY; Yang J; Li Y; Deng ZQ; Ma JC; Chen XX
    PLoS One; 2012; 7(9):e45760. PubMed ID: 23029227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ribosome biogenesis is a downstream effector of the oncogenic U2AF1-S34F mutation.
    Akef A; McGraw K; Cappell SD; Larson DR
    PLoS Biol; 2020 Nov; 18(11):e3000920. PubMed ID: 33137094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Splicing Factor Mutations in Myelodysplasias: Insights from Spliceosome Structures.
    Jenkins JL; Kielkopf CL
    Trends Genet; 2017 May; 33(5):336-348. PubMed ID: 28372848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Precision analysis of mutant U2AF1 activity reveals deployment of stress granules in myeloid malignancies.
    Biancon G; Joshi P; Zimmer JT; Hunck T; Gao Y; Lessard MD; Courchaine E; Barentine AES; Machyna M; Botti V; Qin A; Gbyli R; Patel A; Song Y; Kiefer L; Viero G; Neuenkirchen N; Lin H; Bewersdorf J; Simon MD; Neugebauer KM; Tebaldi T; Halene S
    Mol Cell; 2022 Mar; 82(6):1107-1122.e7. PubMed ID: 35303483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies.
    Taylor J; Lee SC
    Genes Chromosomes Cancer; 2019 Dec; 58(12):889-902. PubMed ID: 31334570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferential occurrence of spliceosome mutations in acute myeloid leukemia with preceding myelodysplastic syndrome and/or myelodysplasia morphology.
    Cho YU; Jang S; Seo EJ; Park CJ; Chi HS; Kim DY; Lee JH; Lee JH; Lee KH; Koh KN; Im HJ; Seo JJ; Park SH; Park YM; Lee JK
    Leuk Lymphoma; 2015; 56(8):2301-8. PubMed ID: 25487075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelodysplastic neoplasm-associated U2AF1 mutations induce host defense defects by compromising neutrophil chemotaxis.
    Gurule NJ; Malcolm KC; Harris C; Knapp JR; O'Connor BP; McClendon J; Janssen WJ; Lee FFY; Price C; Osaghae-Nosa J; Wheeler EA; McMahon CM; Pietras EM; Pollyea DA; Alper S
    Leukemia; 2023 Oct; 37(10):2115-2124. PubMed ID: 37591942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.